e-learning
resources
Berlin 2008
Sunday, 05.10.2008
Animal models of pulmonary fibrosis: mechanisms and therapies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis
L. Farkas, K. Ask, A. Möller, D. Farkas, P. Margetts, J. Gauldie, M. Inman, M. Kolb (Hamilton, ON, Canada; Regensburg, Germany)
Source:
Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Session:
Animal models of pulmonary fibrosis: mechanisms and therapies
Session type:
Thematic Poster Session
Number:
712
Disease area:
Interstitial lung diseases, Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Farkas, K. Ask, A. Möller, D. Farkas, P. Margetts, J. Gauldie, M. Inman, M. Kolb (Hamilton, ON, Canada; Regensburg, Germany). VEGF gene transfer enhances fibrosis but improves pulmonary hemodynamics in experimental pulmonary fibrosis. Eur Respir J 2008; 32: Suppl. 52, 712
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The definition of pulmonary hypertension: history, practical implications and current controversies
Should we screen for hereditary pulmonary hypertension?
Patient with ankylosing spondylitis and pulmonary hypertension
Related content which might interest you:
VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis
Source: Annual Congress 2009 - Pulmonary circulation I
Year: 2009
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Role of IL-11 in vascular function of pulmonary fibrosis patients
Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension
Year: 2019
Macitentan reduces progression of TGF-ß1-induced pulmonary fibrosis and pulmonary hypertension
Source: Eur Respir J, 52 (2) 1701857; 10.1183/13993003.01857-2017
Year: 2018
PP309 – Effect of elexacaftor-tezacaftor-ivacaftor on pulmonary and endothelial function in a patient with advanced cystic fibrosis
Source: ERS Lung Science Conference 2021
Year: 2021
Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis
Source: Eur Respir J 2012; 39: 359-365
Year: 2012
Role of JAK2/STAT3 pathway in vascular function of pulmonary fibrosis patients
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
The effect of pulmonary macrophage transplantation in the pulmonary fibrosis of mice
Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases
Year: 2021
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation
Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling
Year: 2006
VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 574s
Year: 2007
Effect of curcumin on inflammation in experimental pulmonary fibrosis
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
Source: Annual Congress 2011 - Experimental pulmonary hypertension
Year: 2011
Bosentan and improved pulmonary endothelial function in pulmonary arterial hypertension
Source: Eur Respir J 2010; 36: 1483-1485
Year: 2010
MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
Nintedanib has acute pulmonary vasodilatory effects in transgenic Fra2 mice with spontaneous progressive pulmonary hypertension and lung fibrosis.
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Pulmonary arterial hypertension in combined pulmonary emphysema and fibrosis
Source: Annual Congress 2005 - Pulmonary arterial hypertension diagnosis and therapy
Year: 2005
Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema
Source: Eur Respir J 2011; 37: 176-183
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept